clinical trial · NCT07743580
A Study of Secutrelvir in Participants With Coronavirus Disease 2019 (COVID-19) Who Are at High Risk for Progression to Severe Disease
SARS-CoV-2SecutrelvirPlacebo
brief summary
The primary purpose of this study is to evaluate the efficacy and safety of secutrelvir in symptomatic nonhospitalized adult and adolescent participants with COVID-19 who are at high risk for progression to severe disease.
started
Aug 6, 2026
primary completion
Jun 30, 2028
completion
Dec 31, 2028
last updated
Aug 4, 2026
official title
A Phase 3 Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Secutrelvir in Participants With COVID-19 Who Are at High Risk for Progression to Severe Disease
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol